Filgotinib
Based on 31 publication(s) in Google Scholar
Filgotinib (GLPG0634) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib can be used in the study of rheumatoid arthritis and inflammatory bowel disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.77%
- CAS No.: 1206161-97-8
- Formule: C21H23N5O3S
- Masse moléculaire:425.50
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
Description
IC50 & Target
[1]|
JAK1 10 nM (IC50) |
JAK2 28 nM (IC50) |
Tyk2 116 nM (IC50) |
JAK3 810 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
4546 nM
Compound: GLPG0634
|
Antiproliferative activity against mouse BaF3 cells assessed as IL-3-induced inhibition of cell growth incubated for 40 hrs
Antiproliferative activity against mouse BaF3 cells assessed as IL-3-induced inhibition of cell growth incubated for 40 hrs
|
[PMID: 24006460] |
| BaF3 | IC50 |
4546 nM
Compound: 65, GLPG0634
|
Inhibition of JAK2 in IL3-induced human BaF3 cells assessed as cell proliferation
Inhibition of JAK2 in IL3-induced human BaF3 cells assessed as cell proliferation
|
[PMID: 25369270] |
| BaF3 | IC50 |
1.43 μM
Compound: 5
|
Inhibition of JAK1 (unknown origin) expressed in mouse BAF3 cells assessed as antiproliferative activity by cell-based assay
Inhibition of JAK1 (unknown origin) expressed in mouse BAF3 cells assessed as antiproliferative activity by cell-based assay
|
[PMID: 32527540] |
| BaF3 | IC50 |
13.26 μM
Compound: 5
|
Inhibition of JAK3 (unknown origin) expressed in mouse BAF3 cells assessed as antiproliferative activity by cell-based assay
Inhibition of JAK3 (unknown origin) expressed in mouse BAF3 cells assessed as antiproliferative activity by cell-based assay
|
[PMID: 32527540] |
| BaF3 | IC50 |
4.45 μM
Compound: 5
|
Inhibition of JAK2 (unknown origin) expressed in mouse BAF3 cells assessed as antiproliferative activity by cell-based assay
Inhibition of JAK2 (unknown origin) expressed in mouse BAF3 cells assessed as antiproliferative activity by cell-based assay
|
[PMID: 32527540] |
| CWR22R | IC50 |
>10000 nM
Compound: 65, GLPG0634
|
Inhibition of JAK2 in PRL-induced human 22Rv1 cells assessed as pSTAT5
Inhibition of JAK2 in PRL-induced human 22Rv1 cells assessed as pSTAT5
|
[PMID: 25369270] |
| HeLa | IC50 |
1045 nM
Compound: 65, GLPG0634
|
Inhibition of JAK1/JAK2 in OSM-induced human HeLa cells assessed as STAT1 reporter
Inhibition of JAK1/JAK2 in OSM-induced human HeLa cells assessed as STAT1 reporter
|
[PMID: 25369270] |
| T-cell | IC50 |
1.127 nM
Compound: GLPG0634
|
Inhibition of JAK1/TYK2 in human whole blood assessed as reduction in IFN-alpha-induced STAT1 phosphorylation in CD4+ T cells preincubated with compound for 30 mins followed by IFN-alpha addition and measured after 20 mins by flow cytometry analysis
Inhibition of JAK1/TYK2 in human whole blood assessed as reduction in IFN-alpha-induced STAT1 phosphorylation in CD4+ T cells preincubated with compound for 30 mins followed by IFN-alpha addition and measured after 20 mins by flow cytometry analysis
|
[PMID: 24006460] |
| T-cell | IC50 |
17453 nM
Compound: GLPG0634
|
Inhibition of JAK2 in human whole blood assessed as reduction in GM-CSF-induced STAT5 phosphorylation in CD3-positive T cell preincubated with compound for 30 mins followed by GM-CSF addition and measured after 20 mins by flow cytometry analysis
Inhibition of JAK2 in human whole blood assessed as reduction in GM-CSF-induced STAT5 phosphorylation in CD3-positive T cell preincubated with compound for 30 mins followed by GM-CSF addition and measured after 20 mins by flow cytometry analysis
|
[PMID: 24006460] |
| T-cell | IC50 |
1789 nM
Compound: GLPG0634
|
Inhibition of JAK1/JAK3 in human whole blood assessed as reduction in IL-2-induced STAT5 phosphorylation in CD4+ T cells preincubated with compound for 30 mins followed by IL-2 addition and measured after 20 mins by flow cytometry analysis
Inhibition of JAK1/JAK3 in human whole blood assessed as reduction in IL-2-induced STAT5 phosphorylation in CD4+ T cells preincubated with compound for 30 mins followed by IL-2 addition and measured after 20 mins by flow cytometry analysis
|
[PMID: 24006460] |
| T-cell | IC50 |
629 nM
Compound: GLPG0634
|
Inhibition of JAK1 in human whole blood assessed as reduction in IL6-induced STAT1 phosphorylation in CD4+ T cells preincubated with compound for 30 mins followed by IL-6 addition and measured after 20 mins by flow cytometry analysis
Inhibition of JAK1 in human whole blood assessed as reduction in IL6-induced STAT1 phosphorylation in CD4+ T cells preincubated with compound for 30 mins followed by IL-6 addition and measured after 20 mins by flow cytometry analysis
|
[PMID: 24006460] |
| TF-1 | IC50 |
3524 nM
Compound: 65, GLPG0634
|
Inhibition of JAK2 in IL3-induced human TF1 cells assessed as pSTAT5
Inhibition of JAK2 in IL3-induced human TF1 cells assessed as pSTAT5
|
[PMID: 25369270] |
| THP-1 | IC50 |
154 nM
Compound: 65, GLPG0634
|
Inhibition of JAK1/JAK3 in IL4-induced human THP1 cells assessed as pSTAT6
Inhibition of JAK1/JAK3 in IL4-induced human THP1 cells assessed as pSTAT6
|
[PMID: 25369270] |
| THP-1 | IC50 |
3364 nM
Compound: 65, GLPG0634
|
Inhibition of JAK1/JAK2 in IFNgamma-induced human THP1 cells assessed as pSTAT1
Inhibition of JAK1/JAK2 in IFNgamma-induced human THP1 cells assessed as pSTAT1
|
[PMID: 25369270] |
| U2OS | IC50 |
436 nM
Compound: 65, GLPG0634
|
Inhibition of JAK1/TYK2 in IFN-alphaB2-induced human U2OS cells assessed as pSTAT1
Inhibition of JAK1/TYK2 in IFN-alphaB2-induced human U2OS cells assessed as pSTAT1
|
[PMID: 25369270] |
In Vitro
Filgotinib (0.1, 1 and 10 μM) inhibits the differentiation of Th2 cells and Th1 cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Pharmacokinetic analysis of GLPG0634 in mice[1]
| Route | Dose (mg/kg) | C0 or C0 (ng/mL) | Tmax (h) | T1/2 (h) | Cl (L•h/kg) | Vss (L/kg) | F (%) |
| i.v. | 1 | 637 | / | 2.5 | 2.9 | 6 | / |
| p.o. | 5 | 920 | 0.5 | 1.7 | / | / | 100 |